IL213648A - Optimized fc variants and uses thereof - Google Patents
Optimized fc variants and uses thereofInfo
- Publication number
- IL213648A IL213648A IL213648A IL21364811A IL213648A IL 213648 A IL213648 A IL 213648A IL 213648 A IL213648 A IL 213648A IL 21364811 A IL21364811 A IL 21364811A IL 213648 A IL213648 A IL 213648A
- Authority
- IL
- Israel
- Prior art keywords
- variants
- optimized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46760603P | 2003-05-02 | 2003-05-02 | |
US47783903P | 2003-06-12 | 2003-06-12 | |
US10/672,280 US20040132101A1 (en) | 2002-09-27 | 2003-09-26 | Optimized Fc variants and methods for their generation |
PCT/US2004/009298 WO2004099249A2 (en) | 2003-05-02 | 2004-03-26 | Optimized fc variants and methods for their generation |
Publications (2)
Publication Number | Publication Date |
---|---|
IL213648A0 IL213648A0 (en) | 2011-07-31 |
IL213648A true IL213648A (en) | 2017-01-31 |
Family
ID=38312218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL213648A IL213648A (en) | 2003-05-02 | 2011-06-19 | Optimized fc variants and uses thereof |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5226613B2 (en) |
KR (1) | KR100973564B1 (en) |
CA (1) | CA2766627C (en) |
IL (1) | IL213648A (en) |
RU (1) | RU2337107C2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
AU2011258425B2 (en) | 2010-05-27 | 2015-12-10 | Merck Sharp & Dohme Llc | Method for preparing antibodies having improved properties |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
EP2728002B1 (en) | 2011-06-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
TW201817745A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CA2857159C (en) | 2011-11-30 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
JP6290209B2 (en) * | 2012-08-07 | 2018-03-07 | ロシュ グリクアート アーゲー | A composition comprising two antibodies engineered to have reduced and increased effector function. |
KR20230110836A (en) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc region variant |
DK2940135T5 (en) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimerized polypeptide |
JP6456356B2 (en) | 2013-03-15 | 2019-01-23 | ジェネンテック, インコーポレイテッド | IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use |
DK2968495T3 (en) * | 2013-03-15 | 2019-10-14 | Daniel J Capon | HYBRID IMMUNOGLOBULIN CONTAINING A NON-PEPTID-BRO |
RU2015144026A (en) * | 2013-03-15 | 2017-04-20 | Эббви Байотекнолоджи Лтд. | ANTIBODIES AGAINST CD25 AND THEIR APPLICATION |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
PT3027651T (en) * | 2013-08-01 | 2019-05-31 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
NZ724710A (en) | 2014-04-07 | 2024-02-23 | Chugai Pharmaceutical Co Ltd | Immunoactivating antigen-binding molecule |
TW201623333A (en) | 2014-05-13 | 2016-07-01 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
CN106459191B (en) * | 2014-06-12 | 2021-12-10 | 豪夫迈·罗氏有限公司 | Methods of selecting antibodies with modified FcRn interactions |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
EA201791754A1 (en) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS |
JP6931329B2 (en) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
JP7141336B2 (en) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | Anti-myostatin antibodies and methods of use |
CN109689099B (en) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | Composition for preventing or treating IL-8-related diseases |
CN106872713A (en) * | 2016-12-27 | 2017-06-20 | 许洋 | A kind of immunomic mass spectrometry kit and preparation method of trace protein in situ detection |
KR20200099807A (en) * | 2019-02-15 | 2020-08-25 | 아주대학교산학협력단 | Antibody Fragment With Constant Region of Antibody and Uses Thereof |
CN112397159B (en) * | 2019-08-19 | 2024-03-22 | 金色熊猫有限公司 | Automatic entry method and device for clinical test report, electronic equipment and storage medium |
WO2024085632A1 (en) * | 2022-10-18 | 2024-04-25 | 고려대학교 산학협력단 | Human antibody fc domain variant and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL209786B1 (en) * | 1999-01-15 | 2011-10-31 | Genentech Inc | Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant |
EP1553975B8 (en) * | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
-
2004
- 2004-03-26 KR KR1020097009022A patent/KR100973564B1/en active IP Right Review Request
- 2004-03-26 CA CA2766627A patent/CA2766627C/en not_active Expired - Lifetime
- 2004-03-26 RU RU2005137578/13A patent/RU2337107C2/en active
-
2009
- 2009-05-25 JP JP2009141638A patent/JP5226613B2/en not_active Expired - Fee Related
-
2011
- 2011-06-19 IL IL213648A patent/IL213648A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2337107C2 (en) | 2008-10-27 |
CA2766627C (en) | 2019-12-03 |
JP2009209150A (en) | 2009-09-17 |
IL213648A0 (en) | 2011-07-31 |
KR100973564B1 (en) | 2010-08-03 |
KR20090059170A (en) | 2009-06-10 |
RU2005137578A (en) | 2007-06-10 |
JP5226613B2 (en) | 2013-07-03 |
CA2766627A1 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265538B (en) | Optimized fc variants and uses thereof | |
IL213648A0 (en) | OPTIMIZED Fc VARIANTS AND USES THEREOF | |
HK1248731A1 (en) | Immunoglobulin variants and uses thereof | |
EP1606314A4 (en) | Fc REGION VARIANTS | |
EP1539941A4 (en) | Adzymes and uses thereof | |
ZA200603882B (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | |
IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
IL179497A0 (en) | Carboranylporphyrins and uses thereof | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
EP1699485A4 (en) | Anti-hydroxylase antibodies and uses thereof | |
GB0428391D0 (en) | Connection and connection part | |
IL180365A0 (en) | Carboranylporphyrins and uses thereof | |
IL172510A0 (en) | Antibodies and uses thereof | |
EP1612225A4 (en) | Modified acacia and use thereof | |
IL165112A0 (en) | Variant integrinpolypeptides and thereof | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
HK1086853A1 (en) | Dispersion and use thereof | |
GB0318546D0 (en) | Quinoxalinones and their use | |
HK1209049A1 (en) | Survivin-derived peptides and use thereof | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
EP1487547A4 (en) | Physical interaction means and related uses thereof | |
AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
EP1699809A4 (en) | Amniotic-derived peptide and uses thereof | |
GB0312990D0 (en) | Peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |